Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.97) by ($0.36), Briefing.com reports. The business had revenue of $100.50 million for the quarter, compared to the consensus estimate of $103.90 million. Ultragenyx Pharmaceutical […]
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) EVP Karah Herdman Parschauer sold 4,378 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $45.00, for a total value of $197,010.00. Following the transaction, the executive vice president now directly owns 51,982 shares in the […]
Analysts at Cantor Fitzgerald started coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set an “overweight” rating and a $114.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of […]
Should You Buy or Sell Ultragenyx Pharmaceutical Stock? Get The Latest RARE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) insider Dennis Karl Huang sold 389 shares of the stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $45.65, for a total value of $17,757.85. Following the completion of the sale, the insider now directly owns 75,314 shares in the […]